- Article number:
- 2096-1340(2020)05-0060-06
- ZTFLH:
- R735.7
- Code:
- A
References:
[1]中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业委员会,等.原发性肝癌规范化病理诊断指南(2015年版)[J].中华肝胆外科杂志,2015,21(3):145-151.
[2] Wang RH, He LY, Zhou SH. The role of gene sculptor microRNAs in human precancerous lesions[ J] . Onco Tar gets Ther, 2018,11:5667 ? 5675.
[3]钟阿红,郁春晴,董春林,等.miR-124在消化系统肿瘤研究中的进展[J].现代生物医学进展,2016,16(9):1741,1759-1761.
[4]李京涛,郭师,席奇,等.益脾养肝方联合肝动脉化疗栓塞术治疗原发性肝癌的疗效观察[J].陕西中医,2015,36(8):944-945.
[5]何玲玲,赵亚林,杜林林,等.肝结节性病变的病理和影像学表现[J].临床肝胆病杂志,2015,31(9):1547-1550.
[6] Jin Y, Wong YS, Goh Brian KP, et al. Circulating microRNAs as Potential Diagnostic and Prognostic Biomarkers in Hepatocellular Carcinoma[ J] . Scientific reports,2019,9( 1) 10464.
[7]林国桢,汪国营.miR-124与原发性肝癌相关性研究进展[J].中华肝脏外科手术学电子杂志,2018,7(5):433-436.
[8] Wang H, Mao J, Huang Y, et al. Prognostic roles of miR -124 -3p and its target ANXA7 and their effects on cell migration and invasion in hepatocellular carcinoma[ J] .Int J Clin Exp Pathol. 2020,13( 3) :357 ? 370.
[9] Long HD, Ma YS, Yang HQ, et al. Reduced hsa - miR-124 - 3p levels are associated with the poor survival of patients with hepatocellular carcinoma[ J] . Molecular Biology Reports, 2018, 45( 6) : 2615 -2623.
[10] Qi YY, Yao XY, Du XH. Midazolam inhibits proliferation and accelerates apoptosis of hepatocellular carcinoma cells by elevating microRNA ? 124 ? 3p and suppressing PIM ? 1[ J] . IUBMB Life,2020,72( 3) . 452 -464
[11] Cao J, Qiu J, Wang X, et al. Identification of microRNA - 124 in regulation of Hepatocellular carcinoma through BIRC3 and the NF - κB pathway[ J] . J Cancer,2018,9( 17) :3006 ? 3015.
[12] Lang Q, Ling C. MiR -124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA[ J] . Biochem BiophysRes Commun, 2012, 426( 2) :247 -252.
[13] Xu L, Dai W, Li J, et al. Methylation - regulated miR -124 - 1 suppresses tumorigenesis in hepatocellular carcinoma by targeting CASC3 [ J] . Oncotarget, 2016, 7( 18) : 26027 -26041.
Memo
基金项目:国家自然科学基金项目(81904192);陕西省科技厅科研基金(2018KJXX-093,2020SF-338);陕西中医药大学学科创新团队建设项目(2019-YL05)? 作者简介:魏海梁(1978-),副主任医师,研究方向:主要从事中西医结合消化系统疾病的临床研究及教学?E-mail:86888694@qq.com
通讯作者:李京涛,主任医师,医学博士?E-mail:lijingtao555@163.com